Home About us Contact
|
Home About us Contact | ||
|
|
||
Injection Procedure (injection + procedure)
Selected AbstractsLow Back Pain in Older Adults: Are We Utilizing Healthcare Resources Wisely?PAIN MEDICINE, Issue 2 2006Debra K. Weiner MD ABSTRACT Objectives., 1) To examine recent change in prevalence and Medicare-associated charges for non-invasive/minimally invasive evaluation and treatment of nonspecific low back pain (LBP); and 2) to examine magnetic resonance imaging (MRI) utilization appropriateness in older adults with chronic low back pain (CLBP). Design., Two cross-sectional surveys of 1) national (1991,2002) and Pennsylvania (2000,2002) Medicare data; and 2) patients aged ,,65 years with CLBP. Setting., Outpatient data. Participants., Patients aged , 65 years with LBP. Measurements., Study 1: Outpatient national and Pennsylvania Part A Medicare data were examined for number of patients and charges for all patients, and for those with nonspecific LBP. Total number of visits and charges for imaging studies, physical therapy (PT), and spinal injections was also examined for Pennsylvania. Study 2: 111 older adults with CLBP were interviewed regarding presence of red flags necessitating imaging and history of having a lumbar MRI, neurogenic claudication (NC), and back surgery. Results., Study 1: Between 1991 and 2002, there was a 42.5% increase in total Medicare patients, 131.7% increase in LBP patients, 310% increase in total charges, and 387.2% increase in LBP charges. In Pennsylvania (2000,2002), there was a 5.5% increase in LBP patients and 33.2% increase in charges (0.2% for PT, 59.4% for injections, 41.9% for MRI/CT, and 19.3% for X rays). Study 2: None of the 111 participants had red flags and 61% had undergone MRIs (29% with NC, 24% with failed back surgery syndrome). Conclusion., LBP documentation and diagnostic studies are increasing in Medicare beneficiaries, and evidence suggests that MRIs may often be ordered unnecessarily. Injection procedures appear to account for a significant proportion of LBP-associated costs. More studies are needed to examine the appropriateness with which imaging procedures and non-invasive/minimally invasive treatments are utilized, and their effect on patient outcomes. [source] European evaluation of a new hyaluronic acid filler incorporating lidocaineJOURNAL OF COSMETIC DERMATOLOGY, Issue 4 2008Gregor Wahl MD Summary Background, A new dermal filler has been developed with preincorporated lidocaine for the treatment of moderate/severe wrinkles. Aims, Injector and patient evaluation of comfort and aesthetic results obtained with a new hyaluronic acid filler incorporating lidocaine (HAL) following treatment of nasolabial folds. Patients/Methods, Three thousand five hundred and sixty-six patients were recruited by 485 injectors across 16 countries. All patients had previously received facial fillers but now required further treatment. All patients received the new hyaluronic acid filler incorporating lidocaine. Results, Injector assessment of HAL was that it was very easy to inject in > 75% of patients, and postinjection sculpting/massaging was very easy in most patients (> 70%). Both injectors and patients reported low patient pain levels, with patients experiencing less pain during all stages of the HAL injection procedure compared to previous dermal fillers. Over 95% of injectors rated the aesthetic effect of HAL as "excellent" or "good," with 99.1% stating they would recommend treatment to a colleague and 99.4% recommending treatment to other patients. More than 90% of patients were happy with the treatment, and 99% would recommend HAL to friends. Conclusions, The new hyaluronic acid filler incorporating lidocaine provides a more comfortable injection experience and improved aesthetic result for most patients compared with other dermal fillers used previously. [source] Development of a procedure for sustainable in situ aquifer denitrificationREMEDIATION, Issue 2 2003Imtiyaz A. Khan Denitrification experiments have provided data showing the pitfalls and successes in developing a sustainable injection/extraction system in a sand and gravel aquifer. Experiments increase in complexity from continuous injection at one well to automated-pulsed eight well injections. In both continuous and pulsed injection of organic carbon, 40 mg NO3- N l,1 was reduced below the detection limit of < 0.1 mg NO3- N l,1 in the denitrification zones. Under continuous injection, accumulation of bacterial exudates in the vicinity of the injection well resulted in injection well clogging within ten days. Periodic cleaning of the injection well and the adjacent gravel matrix was accomplished by using a tool developed to circulate a cleaning solution composed of 5 percent H2O2 and 0.02 percent NaOCl; but, biofouling could not be eliminated. In the later experiments, acetate became the carbon amendment because ethanol promoted more biomass development. A specialized pulse injection procedure was developed to separate nitrate from acetate-C and was successful in alleviating the proliferation of bacterial exudates without affecting the performance of the denitrification system. Using pulsed injection, a maximum of 72 percent nitrate reduction was accomplished in the extraction well water, and denitrification was sustained for three months without clogging. © 2003 Wiley Periodicals, Inc. [source] Rapid determination of short-chain fatty acids in colonic contents and faeces of humans and rats by acidified water-extraction and direct-injection gas chromatographyBIOMEDICAL CHROMATOGRAPHY, Issue 8 2006Guohua Zhao Abstract Short-chain fatty acids (SCFAs) have attracted much attention recently because of their positive physiological effects. In this work, a rapid and reliable gas chromatographic method for determination of eight SCFAs, in colonic and faecal samples from rats and humans has been developed and validated. The methodology involves extraction of the SCFAs in water before a direct injection procedure on a FFAP capillary column. A stock standard solution containing acetic acid, propionic acid, n -butyric acid, i -butyric acid, n -valeric acid, i -valeric acid, n -caproic acid and n -heptanoic acid was prepared and used. A high line-arity (r2 > 0.9990), low quantification limit (2.38,30.14 µm) and high recovery for most acids were obtained. Acidification of faecal samples was found to be crucial for quantitative determination of the SCFAs, and adjustment of pH to 2,3 was regarded as necessary. Glass wool inserted in the glass liner of the injection port proved effective in preventing the contamination of the column by non-volatiles, and 12% formic acid reduced the ghost peak that appeared gradually after several injections. After validation, the methodology was applied on two faecal samples from rats fed diets containing different amount of dietary fibre and one faecal sample from human fed a normal diet to test the accuracy of the developed method. Copyright © 2005 John Wiley & Sons, Ltd. [source] Practical guidelines for the management of interferon-,-2b side effects in patients receiving adjuvant treatment for melanomaCANCER, Issue 5 2008Expert opinion Abstract Interferon-,-2b (IFN,2b) is the only effective adjuvant therapy for melanoma patients at high risk of recurrence that has been approved by regulatory authorities worldwide. However, IFN toxicities increase the risk of poor treatment compliance and impair the potential for benefit from this agent. A review of the literature demonstrated little recent attention to supportive care in the management of IFN toxicities. An international group of experts with extensive personal experience in the use of IFNs worked together to develop practical guidelines for the use of IFNs. Practical recommendations were developed for patient education on the use of IFN; initial patient assessment and monitoring, including contraindications to the use of IFN, monitoring and managing adverse events, and IFN dose modification and discontinuation; IFN injection procedures; treatment of elderly patients; and use during pregnancy and nursing. Successful adjuvant therapy of melanoma with high-dose IFN requires close compliance with the treatment regimen. Recommendations for the recognition and management of adverse events are designed to enable more patients to complete the full planned course of treatment. Cancer 2008. © 2008 American Cancer Society. [source] | ||||||||||